MMP9 and gastroesophageal junction adenocarcinoma: In addition, andecaliximab, an anti-MMP-9 antibody along with standard chemotherapies such as oxaliplatin, cisplatin and mFOLFOX6 resulted in reduced angiogenic activity in the TME and further improved outcome in patients with gastric and gastroesophageal junction adenocarcinoma (Figure 2E) [127].